{
  "source": "PA-Notification-Sutent.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1101-15\nProgram Prior Authorization/Notification\nMedication Sutent® (sunitinib malate)\nP&T Approval Date 8/2008, 6/2009, 6/2010, 9/2010, 12/2010, 9/2011, 8/2012, 7/2013, 8/2014,\n8/2015, 6/2016, 7/2016, 7/2017, 3/2018, 3/2019, 3/2020, 3/2021, 3/2022,\n3/2023, 3/2024, 3/2025\nEffective Date 6/1/2025\n1. Background:\nSutent® (sunitinib malate) is a tyrosine kinase inhibitor indicated for the treatment of\ngastrointestinal stromal tumor (GIST) after disease progression on or intolerance to Gleevec®\n(imatinib mesylate); treatment of advanced renal cell carcinoma (RCC); adjuvant treatment of\nadult patients at high risk of recurrent RCC following nephrectomy; and treatment of\nprogressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with\nunresectable locally advanced or metastatic disease.\nThe National Cancer Comprehensive Network (NCCN) recommends use of Sutent for\nmedullary, follicular, oncocytic, or papillary thyroid carcinoma; chordoma; meningiomas;\nthymic carcinoma; and treatment of myeloid/lymphoid neoplasms with eosinophilia and FMS-\nlike tyrosine kinase 3 (FLT3) rearrangement. NCCN also approves the use of Sutent for other\nsoft tissue sarcomas: alveolar soft part sarcoma (ASPS), angiosarcoma, solitary fibrous\ntumor/hemangiopericytoma, and extraskeletal myxoid chondrosarcoma.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or under\nsome circumstances. Some states also mandate usage of other Compendium references. Where such\nmandates apply, they supersede language in the benefit document or in the notification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Sutent will be approved based on the following criterio",
    "they supersede language in the benefit document or in the notification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Sutent will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Gastrointestinal Stromal Tumor (GIST)\n1. Initial Authorization\na. Sutent will be approved based on both of the following criteria:\n© 2025 UnitedHealthcare Services, Inc.\n1\n(1) Diagnosis of gastrointestinal stromal tumor (GIST)\n-AND-\n(2) One of the following:\n(a) History of disease progression on, contraindication, or intolerance to Gleevec\n(imatinib), Stivarga (regorafenib), or standard dose Qinlock (ripretinib)\n-OR-\n(b) SDH-deficient GIST\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Sutent will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Sutent therapy\nAuthorization will be issued for 12 months.\nC. Renal Cell Carcinoma (RCC)\n1. Initial Authorization\na. Sutent will be approved based on both of the following criteria:\n(1) Diagnosis of renal cell carcinoma (RCC)\n-AND-\n(2) One of the following:\n(a) Disease has relapsed\n-OR-\n(b) Disease is advanced\n-OR-\n(c) Both of the following:\ni. Used in adjuvant setting\nii. Patient has a high risk of recurrence following nephrectomy\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services, Inc.\n2\n2. Reauthorization\na. Sutent will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Sutent therapy\nAuthorization will be issued for 12 months.\nD. Neuroendocrine and Adrenal Tumors\n1. Initial Authorization\na. Sutent will be approved based on the following criterion:\n(1) Diagnosis of progressive pancreatic neuroendocrine tumors (pNET)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Sutent will be approved based on the following criterion:\n(1) Patient does not show eviden",
    "ive pancreatic neuroendocrine tumors (pNET)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Sutent will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Sutent therapy\nAuthorization will be issued for 12 months.\nE. Soft Tissue Sarcoma\n1. Initial Authorization\na. Sutent will be approved based on the following criterion:\n(1) Diagnosis of one of the following:\n(a) Alveolar soft part sarcoma (ASPS)\n(b) Angiosarcoma\n(c) Solitary fibrous tumor / hemangiopericytoma\n(d) Extraskeletal myxoid chondrosarcoma\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Sutent will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Sutent therapy\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services, Inc.\n3\nF. Thyroid Carcinoma\n1. Initial Authorization\na. Sutent will be approved based on one of the following criteria:\n(1) All of the following:\n(a) Diagnosis of one of the following:\ni. Follicular carcinoma\nii. Oncocytic carcinoma\niii. Papillary carcinoma\n-AND-\n(b) One of the following:\ni. Unresectable locoreginal recurrent disease\nii. Persistent disease\nii. Metastatic disease\n-AND-\n(c) One of the following:\ni. Patient has symptomatic disease\nii. Patient has progressive disease\n-AND-\n(d) Disease is refractory to radioactive iodine treatment\n-OR-\n(2) All of the following:\n(a) Diagnosis of medullary thyroid carcinoma\n-AND-\n(b) One of the following\ni. Patient has progressive disease\nii. Patient has symptomatic metastatic disease\n-AND-\n(c) One of the following:\n© 2025 UnitedHealthcare Services, Inc.\n4\ni. Clinical trials or preferred systemic therapy options are not available or\nappropriate\nii. There is progression on preferred systemic therapy options [e.g. Caprelsa\n(vandetanib), Cometriq (cabozantinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Sutent will be approved based on the following ",
    "eferred systemic therapy options [e.g. Caprelsa\n(vandetanib), Cometriq (cabozantinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Sutent will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Sutent therapy\nAuthorization will be issued for 12 months.\nG. Chordoma\n1. Initial Therapy\na. Sutent will be approved based on the following criterion:\n(1) Diagnosis of recurrent chordoma\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Sutent will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Sutent therapy\nAuthorization will be issued for 12 months.\nH. Central Nervous System Cancer\n1. Initial Therapy\na. Sutent will be approved based on all of the following criteria:\n(1) Diagnosis of surgically inaccessible meningiomas\n-AND-\n(2) One of the following:\n(a) Disease is recurrent\n(b) Disease is progressive\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n5\n(3) Further radiation is not possible\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Sutent will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Sutent therapy\nAuthorization will be issued for 12 months.\nI. Thymic Carcinoma\n1. Initial Therapy\na. Sutent will be approved based on the following criteria:\n(1) Diagnosis of thymic carcinoma\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Sutent will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Sutent therapy\nAuthorization will be issued for 12 months.\nJ. Myeloid/Lymphoid Neoplasms\n1. Initial Authorization\na. Sutent will be approved based on both of the following criteria:\n(1) Diagnosis of lymphoid, myeloid, or mixed lineage neoplasms with eosinophilia\n-AND-\n(2) Patient has a FMS-like tyrosine kinase 3 (FLT3) rearrangement in chronic or blast\nphase\nAuthoriza",
    "g criteria:\n(1) Diagnosis of lymphoid, myeloid, or mixed lineage neoplasms with eosinophilia\n-AND-\n(2) Patient has a FMS-like tyrosine kinase 3 (FLT3) rearrangement in chronic or blast\nphase\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Sutent will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Sutent therapy\n© 2025 UnitedHealthcare Services, Inc.\n6\nAuthorization will be issued for 12 months.\nK. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of\nEvidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Sutent [package insert]. New York, NY: Pfizer Labs; August 2021.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nwww.nccn.org. Accessed January 30, 2025..\nProgram Prior Authorization/Notification - Sutent® (sunitinib malate)\nChange Control\n8/2014 Annual review with updated criteria for thyroid carcinoma. Expanded\ndisease description for RCC. Updated Background and References.\n9/2014 Administrative change - Tried/Failed exemption for State of New Jersey\nremoved.\n8/2015 Annual review. Updated thyroid cancer and lung neuroendocrine tumor\ncriteria. Added new criteria for meningiomas and thymic carcinoma.\nUpdated background and re",
    "for State of New Jersey\nremoved.\n8/2015 Annual review. Updated thyroid cancer and lung neuroendocrine tumor\ncriteria. Added new criteria for meningiomas and thymic carcinoma.\nUpdated background and references.\n6/2016 Annual review. Updated thyroid cancer criteria to include persistent\ndisease. Updated background and references.\n7/2016 Updated thyroid and thymic cancer criteria.\n7/2017 Annual review. Updated background and criteria removing off label\ncriteria for lung neuroendocrine tumors as no longer recommended by\nNCCN. Updated reference.\n3/2018 Updated background and criteria to include new labeled indication of\nadjuvant therapy for high risk RCC following nephrectomy. Updated\nreferences.\n© 2025 UnitedHealthcare Services, Inc.\n7\n3/2019 Annual review with no changes to coverage criteria. Updated references.\n3/2020 Annual review. Added general NCCN recommendations for use criteria.\nUpdated reference.\n3/2021 Annual review. Added NCCN recommendation for Myeloid/Lymphoid\nNeoplasms to background and updated treatment criteria. References\nupdated.\n3/2022 Annual review. Updated renal cell and neuroendocrine carcinoma criteria\nper NCCN guidelines. Updated references.\n3/2023 Annual review. Updated Myeloid/Lymphoid and Thymic cancer criteria\nper NCCN guidelines. Updated reference. Added state mandate footnote.\n3/2024 Annual review. Updated GIST, neuroendocrine/adrenal tumors, and\nthyroid carcinoma per NCCN recommendations.\n3/2025 Annual review. Updated soft tissue sarcoma to include coverage for\nextraskeletal myxoid chondrosarcoma per NCCN guidelines. Updated\nreferences.\n© 2025 UnitedHealthcare Services, Inc.\n8"
  ]
}